secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2023-12-11T23:59:59+00:00
Accession:  0001140361-23-057155
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics announces 2023 annual meeting results; all director nominees elected
--------------------------------------------------------------------------------

- All 11 director nominees elected; highest vote total for Kary Eldred at 25,603,577 for.
- Ratification of Cherry Bekaert LLP as auditor approved: 44,481,830 for, 252,254 against.
- Amendment to 2019 Omnibus Equity Incentive Plan to add 3,000,000 shares approved: 23,901,293 for, 1,923,578 against, 18,910,166 broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036123057155/0001140361-23-057155-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036123057155/ef20016443_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-057155

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer